Pharmacoeconomic analysis of therapies for pediatric patients

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 4, Issue 5, 2004, Pages 483-487

  Raisch, Dennis W ^a,b   Holdsworth, Mark T ^b   Marshik, Patricia L ^b   Campbell, Heather M ^a  

^a University of New Mexico   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BUDESONIDE; CORTICOSTEROID; ERYTHROPOIETIN; FLUTICASONE PROPIONATE; METOCLOPRAMIDE; ONDANSETRON; RAZOXANE;

AGE; ANEMIA; ASTHMA; BLOOD TRANSFUSION; CANCER RESEARCH; CARDIOTOXICITY; CHILD; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE CONTROL; DOSE RESPONSE; DRUG APPROVAL; DRUG LABELING; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; EDITORIAL; EWING SARCOMA; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH ECONOMICS; HEART PROTECTION; HUMAN; INFECTION; LAW SUIT; LEUKEMIA; LYMPHOMA; MEDICAL RESEARCH; MORBIDITY; NAUSEA; NEUROBLASTOMA; OSTEOSARCOMA; OUTCOMES RESEARCH; PEDIATRICS; PRACTICE GUIDELINE; QUALITY OF LIFE; RARE DISEASE; RHABDOMYOSARCOMA; RISK ASSESSMENT; VOMITING;

EID: 5444232509     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.4.5.483     Document Type: Editorial

References (30)

1. Alemayehu B, Warner KE. The lifetime distribution of healthcare costs. Health Serv. Res. 39, 627-642 (2004).
2. Ackerman TF. The ethics of drug research in children. Paediatr. Drugs 3, 29-41 (2001).
3. Holdsworth MT. Pediatric drug research - the road less traveled. Ann. Pharmacother. 37, 586-591 (2003).
4. Conroy S, McIntyre J, Choonara I, Stephenson T. Drug trials in children: problems and the way forward. Br. J. Clin. Pharmacol. 49, 93-97 (2000).
5. Robertson WO. Chemicals, children and research dollars. Vet. Hum. Toxicol. 40, 308-309 (1998).
6. Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am. J. Med. 62, 200-208 (1977).
7. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N. Engl. J. Med. 324, 808-415 (1991).
8. Agarwala S, Kumar R, Bhatnagar V, Bajpai M, Gupta DK, Mitra DK. High incidence of adriamycin cardiotoxicity in children even at low cumulative doses: role of radionuclide cardiac angiography. J. Pediatr. Surg. 35, 1786-1789 (2000).
9. Seifert CF, Nesser ME, Thompson DF. Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity, Ann. Pharmacother. 28, 1063-1072 (1994).
10. Wexler LH, Andrich MP, Venzon D et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J. Clin. Oncol. 14, 362-372 (1996).
11. Wexler LH. Ameliorating anthracycline cardiotoxicity in children with cancer: clinical trials with dexrazoxane. Semin. Oncol. 25, 86-92 (1998).
12. Lipshultz SE, Rifai N, Dalton VM et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N. Engl. J. Med. 351, 145-153 (2004 ).
13. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266, 1672-1677 (1991).
14. Henry DH, Abels RI. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin. Oncol. 21, 21-28 (1994).
15. Iconomou G, Koutras A, Rigopoulos A, Vagenakis AG, Kalofonos HP. Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: results of a randomized, controlled trial. J. Pain Symptom Manage. 25, 512-518 (2003).
16. Case DC Jr, Bukowski RM, Carey RW et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J. Natl. Cancer. Inst. 85, 801-806 (1993).
17. Koeller JM. Clinical guidelines for the treatment of cancer-related anemia. Pharmacotherapy 18, 156-169 (1998).
18. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin α in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times weekly dosing. J. Clin. Oncol. 19, 2875-2882 (2001).
19. Rizzo JD, Lichtin AE, Woolf SH et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J. Clin. Oncol. 20, 4083-4107 (2002).
20. Feusner J, Hastings C. Recombinant human erythropoietin in pediatric oncology: a review. Med. Pediatr. Oncol. 39, 463-468 (2002).
21. Leal Noval SR, Jara Lopez I. Do multiple blood transfusions predispose for a higher rate of nonblood-related infection complications? Clin. Microbiol. Infect. 8, 383-387 (2002).
22. Claridge JA, Sawyer RG, Schulman AM, McLemore EC, Young JS. Blood transfusions correlate with infections in trauma patients in a dose-dependent manner. Am. Surg. 68, 566-572 (2002).
23. Phillips J, Beam S, Brinker A et al. Retrospective analysis of mortalities associated with medication errors. Am. J. Health Syst. Pharm 58, 1835-1841 (2001).
24. Warner JO, Naspitz CK. Third International Pediatric Consensus statement on the management of childhood asthma. International Pediatric Asthma Consensus Group. Pediatr. Pulmonol. 25, 1-17 (1998).
25. Peat JK, van den Berg RH, Green WF, Mellis CM, Leeder SR, Woolcock AJ. Changing prevalence of asthma in Australian children. Br. Med. J. 308, 1591-1596 (1994).
26. Mannino DM, Homa DM, Akinbami LJ, Moorman JE, Gwynn C, Redd SC. Surveillance for asthma: United States, 1980-1999. MMWR Surveill. Summ. 51(1), 1-13 (2002).
27. Zbrozek AS, Cantor SB, Cardenas MP, Hill DP Jr. Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting. Am. J. Hosp. Pharm. 51, 1555-1563 (1994).
28. Holdsworth MT, Raisch DW, Winter SS, Chavez CM. Assessment of the emetogenic potential of intrathecal chemotherapy and response to prophylactic treatment with ondansetron. Support Care Cancer 6, 132-138 (1998).
29. Holdsworth MT, Adams VR, Raisch DW, Wood JG, Winter SS. Computerized system for outcomes-based antiemetic therapy in children. Ann. Pharmacother. 34, 1101-1108 (2000).
30. Hart C, Chesson R. Children as consumers. Br. Med. J. 316, 1600-1603 (1998).